Table 2. Overlapping genes between different treatments.
Treatment/cells | Rituximab vs. LT20 | Anti-IgM vs. Anti-IgM-F (ab')2 | Anti-IgM/F (ab)2 vs. anti-IgG | Anti-BCR vs. anti-CD20 |
OciLy18 | NA | 312 | 102 | NA |
Z138 | NA | 246 | 181 | NA |
REC1 | 98* | 977 | 768 | 89 |
SUDHL4 | 436 | NA | NA | 342** |
*Intersection of genes deregulated by rituximab, rituximab-F(ab')2 and LT20.
**Only anti-IgG antibody as anti-BCR treatment.